Dendreon (NASDAQ:DNDN) has posted its results. The actual EPS and revenues don’t matter because of the stage of the company. But the company did lower its total expenses to $23.4 million. That compares to $26.3 million from Q2 2006 and roughly $28 million last quarter. Those expenses included options costs of $1.3 million and $2.9 million, respectively.
So the company slowed its cash burn rate, and that is what we wanted to see. Unfortunately the company made no new developments in the "highlights" or "disclosures." Unless the company announces some unexpected FDA developments or unless it announces a surprise partner, this one sounds like there could be a continued news vacuum.
Jon C. Ogg
August 7, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Are You Ahead, or Behind on Retirement? (sponsor)
If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: are you ahead, or behind on your retirement goals?
Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With SmartAsset’s free tool, you can connect with vetted financial advisors in minutes.
Why wait? Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.